← Back to Home

Innoviva

NASDAQ: INVA ↗$21.07 USD~$1.5B MCAP
#Long-Acting Oral Therapeutics#Critical Care#Infectious Disease#Specialty Pharma

Innoviva Inc. (NASDAQ: INVA) is a specialty pharmaceutical company with a diversified portfolio of marketed therapeutics and a growing focus on long-acting drug delivery. The company is reviving the Lyndra Therapeutics long-acting oral drug platform, originally developed at Bob Langer's MIT lab, with Langer and Janet Woodcock as senior advisors.

Company Info

Sector:Pharmaceutical / Specialty Therapeutics & Drug Delivery
Headquarters:Waltham, Massachusetts, USA
Founded:2000
Website:www.innoviva.com/

Upcoming Milestones & Key Dates

2026-06-18
Corporate

Lyndra platform revival announcement

2026-Q4
R&D

Lyndra lead program candidate selection

2027-H1
Regulatory

Potential first Lyndra-program IND filing

Clinical Development Pipeline

Lyndra Long-Acting Oral Platform

Target: Long-acting oral dosage form
Multiple chronic indications (TBD)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Innoviva Specialty Therapeutics Portfolio

Target: Multiple approved assets
Critical care and infectious disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Xerava (eravacycline)

Target: Tetracycline antibiotic
Complicated intra-abdominal infections
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Mark Chin

Chief Executive Officer

Jennifer Ziegler

Chief Operating Officer

Robert Langer

Senior Advisor (Lyndra platform)

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →